8-K
filed June 2, 2026, 4:05 PM ET
ticker TSHA
CIK 0001806310
other
confidence high
sentiment neutral
materiality 0.15
Taysha Gene Therapies annual meeting elects directors, ratifies auditor, approves say-on-pay
Taysha Gene Therapies, Inc.
- Shareholders elected Sean P. Nolan (169.1M for) and Laura Sepp-Lorenzino (150.1M for) as directors until 2029.
- Deloitte & Touche ratified as independent auditor for FY2026 with 243.8M votes for.
- Non-binding advisory vote on named executive officer compensation approved: 168.1M for vs 36.4M against.
- Advisory vote on frequency of say-on-pay: annual basis chosen with 203.8M votes for one year.
- Approximately 84.86% of outstanding shares were represented at the meeting.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Taysha Gene Therapies, Inc. shareholders approved Approval of, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2026-06-01 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-01
Exact text from the filing
Proposal No. 3 : Approval of, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the proxy statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the compensation of the Company’s named executive officers 168,142,551 36,396,784 345,291 Broker Non-Votes: 38,973,186
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Taysha Gene Therapies, Inc. shareholders approved Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company's named executive officers at the 2026-06-01 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-06-01
Exact text from the filing
Proposal No. 4 : Indication of, on a non-binding advisory basis, the preferred frequency of future stockholder advisory votes on the compensation of the Company’s named executive officers. The votes were cast as follows: One Year Two Years Three Years Abstained Advisory indication of preferred frequency of future shareholder advisory votes on Company’s named executive officer compensation 203,825,717 360,924 630,378 67,607 Broker Non-Votes: 38,973,186
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Taysha Gene Therapies, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting at the 2026-06-01 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-01
Exact text from the filing
Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Sean P. Nolan 169,142,295 35,742,331 Laura Sepp-Lorenzino, Ph.D. 150,094,517 54,790,109 Broker Non-Votes: 38,973,186 Both nominees were elected.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Taysha Gene Therapies, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-01 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-01
Exact text from the filing
Proposal No. 2 : Ratification of the selection of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of Deloitte & Touche LLP 243,814,085 25,551 18,176 Broker Non-Votes: 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.